A Role for Harm Reduction
Without doubt, the best way for people to avoid the health risks of smoking is to never begin smoking, and the best way for those who already smoke to minimize their health risks is to quit promptly. Even after years of smoking, quitting reduces risk both immedi ately and in the long-term for many tobaccorelated conditions. Several types of smoking cessation programs, some aimed at individuals and some at communities, have been shown to Thus, while 70 percent of smokers say they want to quit, and 34 percent of smok ers attempt to quit each year, only 10 percent of those who try to quit actually break their addiction and remain tobaccofree for a year.
Numerous products that make explicit or implied claims to lower the health risks of cigarettes and other forms of to bacco have been in troduced into the U.S. marketplace-and there is a strong like lihood of more prod ucts and increased marketing in the near future.
be modestly effective. For many smokers, however, quitting proves difficult. The simple fact is tobacco contains nicotine, which is both pleasurable to the user and highly addictive. Thus, while 70 percent of smokers say they want to quit, and 34 percent of smokers attempt to quit each year, only 10 percent of those who try to quit actually break their addiction and remain tobacco-free for a year.
Because many people cannot or will not stop using tobacco, and because many adolescents will continue to experiment with things "taboo," there almost certainly will remain a significant population whose health is at risk from smo k ing. Indeed, it has been predicted that even with the most intensive application of the most effective programs for abstinence and cessation, at least 10 percent to 15 percent of adults in the United States would continue to smoke.
The huge personal and public toll of smoking has prompted the search for means to reduce the harm associated with tobacco use for those individuals who continue to smoke. Numerous products that make explicit or implied claims to lower the health risks of cigarettes and other forms of tobacco have been intro duced into the U.S. marketplace-and there is a strong likelihood of more prod ucts and increased marketing in the near future.
In light of such developments, the U.S. Food and Drug Administration asked the Institute of Medicine, an arm of the National Academy of Sciences, to con vene a committee of experts to lay out the scientific methods and standards by which these products and their effect on public health could be assessed. 
Products Aimed at Risk Reduction
The committee focused on two types of products, both of which are intended to reduce tobacco-related exposure and potentially reduce the risk of disease compared to conventional tobacco products.
The first type includes tobacco and ciga rette-like products that result in potentially decreased emission of some toxicants. Some of these products are made with different types of tobacco or additives, or they are made using different methods of curing, blending, or processing the tobacco. Others use modified delivery systems that change the composition of the smoke that the user inhales by such means as reducing the burning temperature of the tobacco, diluting the smoke with air, or adding special "carri ers" for smoke particles.
The second type includes several phar maceutical agents, some of which are cur rently approved for short-term use in Trends in cigarette smoking* among persons aged � 18 years, by sex-United States, 1955 -1997 . SOURCE: CDC/1955 1965 -1997 smoking cessation. These products might be used long-term to maintain cessation or concomitantly with continued but decreased consumption of cigarettes or other conventional forms of tobacco. Many of these products contain nicotine incorpo rated into patches, gums, oral inhalers, and nasal sprays. Others contain particular antidepressants that reduce the craving for tobacco.
Although both types of products could potentially result in reduced exposure to toxicants from a given instance of tobacco use, such reduced exposure does not necessarily assure reduced risk to the individual user or reduced harm to the larger population. At the population level, for example, the potential benefits might be reduced if some people, perceiving these products to be safer, begin us ing tobacco who otherwise would not have done so, if some smokers who might have quit do not, or if some former smokers resume smoking. Therefore, and in order to avoid any misinterpretation, the committee chose to use the generic term "potential reduced-exposure products," or PREPs, to describe these products. Despite any potential harm reduction that PREPs may offer, the use of tobacco in any form poses greater risk than having no exposure to tobacco at all.
What We Know
In considering these products, the committee examined four basic questions: (1) Does use of a product decrease exposure to the harmful substances in tobacco? (2) Is this decreased exposure associated with decreased harm to health? (3) Since actual health effects associated with these products might not appear for many years, are there surrogate indicators of their effects that could be measured in a time frame sufficient for product evaluation? (4) What are the public health impli cations of tobacco harm-reduction products? Where answers could not be determined, the committee was asked to propose a broad strategy by which the knowl edge base should be assembled.
The committee reached the following principal conclusions regarding these questions: • There are sufficient data to suggest that, for many diseases attributable to tobacco use, reducing risk of disease by reducing exposure to tobacco toxicants is biologically and clinically feasible.
• No PREPs have yet been evaluated comprehensively enough (including for a sufficient time) to provide evidence for concluding that they are associated with a reduced risk of disease compared to conventional tobacco use. Such impact likely will not be directly or conclusively demo nstrated for many years.
• Surrogate measures of tobacco-related diseases exist that could be used to give guidance or to help predict whether or not PREPs are likely to be riskreducing. Available candidate surrogate measures must be further validated and more must be developed in order to be useful for PREP evaluation and regulation.
• PREPs exist that have been or could be demonstrated to reduce exposure to some of the toxicants in most conventional tobacco products.
• Regulation of all tobacco products (as recommended in the 1994 IOM report Growing up Tobacco Free: Preventing Nicotine Addiction in Children and Youths), including all PREPs, is a necessary precondition for assuring a scientific basis for judging the effects of using PREPs and for assuring that the health of the public is protected. Regulation could assure that adequate research, on everything from smoke chemistry and toxicology to long-term epidemiology, is conducted and that the public receives reliable information as to the risks and benefits of PREPs.
• The public health impact of PREPs is unknown. They are potentially bene ficial, but the net impact on population health could, in fact, be negative.
A Comprehensive Approach to Tobacco Harm Reduction
Following on these general conclusions, tobacco harm reduction efforts, if conducted properly, could lead to reduced tobacco-related morbidity and mortal ity for those people who cannot or will not give up tobacco. Such an effort neces sarily relies on public health tools such as research, surveillance, and regulation aimed at improving education and communication directed to the consumer.
Research
In order to strengthen the evidence base for harm reduction, the committee presented a more specific research agenda for assessing harm-reduction products. The plan identified five general scientific areas that should be explored:
1. Description of the dose-response relationship between tobacco smoke and/or constituent exposure and health outcomes. There are more than 4,000 dif ferent chemicals in tobacco smoke, many of them toxic. For the most part, the data are insufficient to accurately describe the relationship of tobacco use and dis ease formation at the level of detail that would establish all casual agents or the exact dose-response relationship. Consequently, the confidence with which the potential benefits or risks of PREPs can be extrapolated, especially at low doses, is uncertain.
2. Identification and development of surrogate markers for disease. Possible markers include, for example, measures of inflammation and vascular activation, which may be related to measures of cardiovascular physiology and, ultimately, reflect the risk of clinical cardiovascular disease or lung disease. Biomarkers of genetic damage in blood, sputum, urine, and internal organs may indicate early carcinogenic processes and risk of cancer development. Ideally, a set of behavioral markers also might be developed to monitor such things as the substitution of PREPs for smoking cessation or the increase in initiation due to the availability of PREPs.
3. Preclinical research. Animal models and in vitro testing can contribute to the design and evaluation of PREPs. In particular, the new technologies of genomics and proteomics have great potential for evaluating and comparing the effects of tobacco exposure and use of PREPs on gene translation and expression in cancerous and noncancerous diseases.
4. Short-term clinical and epidemiological studies. Some effects of PREPs could be detected by epidemiological studies, by measurement of intermediate disease markers, or by clinical studies of smokers who are unwilling or unable to quit but are willing to use PREPs compared to a control group of users of conventional tobacco products. Validated biomarkers of disease, when available, should be developed in these studies in order to assess potential risk reduction within a practical time-frame. Human studies also are required for evaluating the relationship of such various factors as individual smoking history, environment, gender, race, and diet to disease risk and likelihood of harm reduction.
5. The role of long-term epidemiological studies and surveillance. Most tobacco-related diseases develop clinically over several years. Thus, the only direct and definitive way to assess the value of PREPs is to monitor the health outcomes of users compared to control groups over an extended period.
To help in organizing the scientific base for evaluation of PREPs, the committee made use of a risk assessment framework similar to that used to gauge the health risks for other environmental and occupational exposures. In particular, the committee turned to a 1983 National Research Council report called Risk Assessment in the Federal Government. Known as "The Red Book," the report outlined several basic steps in risk assessment. These steps include hazard identification (Does the toxicant cause the adverse effect?), dose-response assessment (What is the relationship between toxicant dose and disease incidence in humans?), exposure assessment (What exposures are currently experienced or anticipated under different circumstances?), and risk characterization (What is the estimated incidence of the adverse effect in a given population?). The process also must take into account public health, social, economic, and political considerations. While fully addressing research needs will take years of concerted effort, im mediate actions also are required to successfully achieve a goal of harm reduction. Today, there is little public authority over tobacco products of any type. Thus, the committee concluded that in order to obtain the best available scientific evalua tion of current and emerging PREPs, and to provide the best advice on these products to the public, some national authority over PREPs is needed. Only a comprehensive program of surveillance and regulation focused to assure the pub lic is accurately informed about the health effects of the new products and to as sess the relative toxicity of all products offers a reasonable possibility of achiev ing a net gain in health from use of PREPs.
Surveillance
Toward this end, the committee recommended development of a national sur veillance system to assess the relative contribution of PREPs to the health of the public. This system would collect information on a range of elements necessary to understand the population impact of tobacco products and PREPs, including con sumer attitudes and beliefs, product characteristics and usage patterns, marketing messages, rates of people who start or quit using tobacco products, and the prevalence of major smoking-related diseases, population level biomarkers indi cating actual degree of tobacco or tobacco smoke exposure, among other infor mation. The tobacco industry would be required to provide data on the constitu ents of tobacco products as well as on product distribution and sales.
Implementation
In order to best implement the scientific and policy recommendations made, the committee further recommended development of a national regulatory system for all modified tobacco products with risk-reduction or exposure-reduction claims, explicit or implicit, and for any other products offered to the public to promote reduction or cessation of tobacco use. For this purpose, the regulatory framework outlined is narrow and focused exclusively on evidence supporting claims and any necessary powers required to assess PREPs, pharmaceutical or tobacco-related. This network would build on the foundation of existing food and drug laws, with adaptations to take into account the unique history and toxicity of tobacco prod ucts.
In sum, the committee determined that it is both feasible and desirable to im plement a comprehensive, scientifically based program that promotes and assesses the use of PREPs. Such a system must be carefully implemented and must incor porate the following features:
• Manufacturers have incentive to develop and market products that reduce exposure to tobacco toxicants and that have a reasonable prospect of reducing the risk of tobacco-related disease.
• Consumers are accurately informed of all of the known, unknown, likely, and potential consequences of using these products.
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• Promotion, advertising, and labeling of these products are firmly regulated to prevent false or misleading claims.
• Health effects of using PREPs are monitored on a continuing basis.
• Basic, clinical, and epidemiological research is conducted to establish the potential use of PREPs for reducing risks for disease in individuals and for re ducing harm to the population as a whole.
• Harm reduction is implemented as a component of a comprehensive na tional tobacco control program that emphasizes abstinence-oriented prevention and treatment.
As outlined here, a comprehensive approach that utilizes scientific research, surveillance, and regulatory tools is necessary for the realization of the potential individual and societal benefits of tobacco harm reduction.
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